- Home
- GHRS vs MYGN Comparison
GHRS vs MYGN Comparison
Compare GHRS & MYGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GHRS
- MYGN
- Stock Information
- Founded
- GHRS 2018
- MYGN 1991
- Country
- GHRS Ireland
- MYGN United States
- Employees
- GHRS N/A
- MYGN N/A
- Industry
- GHRS Biotechnology: Pharmaceutical Preparations
- MYGN Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Sector
- GHRS Health Care
- MYGN Health Care
- Exchange
- GHRS Nasdaq
- MYGN Nasdaq
- Market Cap
- GHRS 774.1M
- MYGN 642.0M
- IPO Year
- GHRS 2021
- MYGN 1995
- Fundamental
- Price
- GHRS $11.94
- MYGN $7.24
- Analyst Decision
- GHRS Strong Buy
- MYGN Hold
- Analyst Count
- GHRS 8
- MYGN 13
- Target Price
- GHRS $30.63
- MYGN $13.50
- AVG Volume (30 Days)
- GHRS 190.5K
- MYGN 1.4M
- Earning Date
- GHRS 11-13-2025
- MYGN 11-06-2025
- Dividend Yield
- GHRS N/A
- MYGN N/A
- EPS Growth
- GHRS N/A
- MYGN N/A
- EPS
- GHRS N/A
- MYGN N/A
- Revenue
- GHRS N/A
- MYGN $832,900,000.00
- Revenue This Year
- GHRS N/A
- MYGN $0.17
- Revenue Next Year
- GHRS N/A
- MYGN $6.19
- P/E Ratio
- GHRS N/A
- MYGN N/A
- Revenue Growth
- GHRS N/A
- MYGN 3.83
- 52 Week Low
- GHRS $6.00
- MYGN $3.76
- 52 Week High
- GHRS $20.50
- MYGN $29.30
- Technical
- Relative Strength Index (RSI)
- GHRS 34.28
- MYGN 65.47
- Support Level
- GHRS $13.71
- MYGN $6.73
- Resistance Level
- GHRS $14.59
- MYGN $7.05
- Average True Range (ATR)
- GHRS 0.76
- MYGN 0.40
- MACD
- GHRS -0.12
- MYGN 0.07
- Stochastic Oscillator
- GHRS 3.99
- MYGN 72.28
About GHRS GH Research PLC
GH Research PLC is a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients by developing a practice-changing treatment for depression. Its initial focus is on developing novel and proprietary mebufotenin therapies for the treatment of patients with Treatment-Resistant Depression, or TRD. Its portfolio currently includes GH001, a proprietary inhalable mebufotenin product candidate, and GH002, a proprietary intravenous mebufotenin product candidate. The group has only a single segment: Research and Development.
About MYGN Myriad Genetics Inc.
Myriad Genetics Inc is a molecular diagnostics company that provides testing services designed to assess an individual's risk of developing a disease. The firm produces MyRisk, a 48-gene panel capable of identifying the elevated risk of developing 11 types of cancer. Other diagnostic products include BRACAnalysis CDx, the FDA-approved companion diagnostic for PARP inhibitors; GeneSight, which helps improve responses to psychotropic drugs for patients suffering from depression; and Prequel, a noninvasive prenatal test. Precise Oncology Solutions, launched in 2022, combines Precise Tumor with companion diagnostic and prognostic tests such as MyChoice CDx, Prolaris, and EndoPredict. The firm also offers pharma and biotech companies biomarker discovery and companion diagnostic services.